Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023)
The blood–brain barrier (BBB) system safeguards cerebral tissues. This hypothetical barrier within the brain serves a dual purpose: defending against pathogens and hindering the entry of drug molecules. The protection conferred by the BBB holds immense importance, as drug administration for cerebrov...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Journal of Medical Evidence |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/JME.JME_155_23 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850184876169363456 |
|---|---|
| author | Raja Chakraverty Samarendra Nath Samui Tatini Debnath |
| author_facet | Raja Chakraverty Samarendra Nath Samui Tatini Debnath |
| author_sort | Raja Chakraverty |
| collection | DOAJ |
| description | The blood–brain barrier (BBB) system safeguards cerebral tissues. This hypothetical barrier within the brain serves a dual purpose: defending against pathogens and hindering the entry of drug molecules. The protection conferred by the BBB holds immense importance, as drug administration for cerebrovascular and neurological disorders involves a rigorous biochemical process. At the membrane level, the BBB comprises a variety of receptors that enhance the selectivity of drug delivery. A systematic review was meticulously designed, encompassing recent bibliographic databases and compendial inquiries employing standardised keywords. PubMed and Cochrane searches were conducted, yielding pertinent articles within the scope of this study for 2017–2023. The medical treatment of cerebral ischaemia demands the prompt infusion of an external thrombolytic agent into the systemic circulation, a process that necessitates passage through the BBB. One significant drawback of existing thrombolytic agents is their limited affinity for the BBB and, consequently, for brain tissue. In clinical scenarios, it is common to administer high doses of thrombolytic drugs to facilitate their crossing of the BBB, leading to drug-related toxicities that can result in neuronal damage at the tissue level. Furthermore, this research delved into the utilisation of nanoscale engineering and continuous monitoring of therapeutic approaches designed to mitigate drug-related toxicity. |
| format | Article |
| id | doaj-art-f6fed5e37e7e4324ae9d6b9ad2e3f06a |
| institution | OA Journals |
| issn | 2667-0720 2667-0739 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Medical Evidence |
| spelling | doaj-art-f6fed5e37e7e4324ae9d6b9ad2e3f06a2025-08-20T02:16:55ZengWolters Kluwer Medknow PublicationsJournal of Medical Evidence2667-07202667-07392025-01-0161536410.4103/JME.JME_155_23Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023)Raja ChakravertySamarendra Nath SamuiTatini DebnathThe blood–brain barrier (BBB) system safeguards cerebral tissues. This hypothetical barrier within the brain serves a dual purpose: defending against pathogens and hindering the entry of drug molecules. The protection conferred by the BBB holds immense importance, as drug administration for cerebrovascular and neurological disorders involves a rigorous biochemical process. At the membrane level, the BBB comprises a variety of receptors that enhance the selectivity of drug delivery. A systematic review was meticulously designed, encompassing recent bibliographic databases and compendial inquiries employing standardised keywords. PubMed and Cochrane searches were conducted, yielding pertinent articles within the scope of this study for 2017–2023. The medical treatment of cerebral ischaemia demands the prompt infusion of an external thrombolytic agent into the systemic circulation, a process that necessitates passage through the BBB. One significant drawback of existing thrombolytic agents is their limited affinity for the BBB and, consequently, for brain tissue. In clinical scenarios, it is common to administer high doses of thrombolytic drugs to facilitate their crossing of the BBB, leading to drug-related toxicities that can result in neuronal damage at the tissue level. Furthermore, this research delved into the utilisation of nanoscale engineering and continuous monitoring of therapeutic approaches designed to mitigate drug-related toxicity.https://journals.lww.com/10.4103/JME.JME_155_23blood–brain barrierdrug toxicitynanoscale biomaterialssolid lipid nanoparticlesthrombolytics |
| spellingShingle | Raja Chakraverty Samarendra Nath Samui Tatini Debnath Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023) Journal of Medical Evidence blood–brain barrier drug toxicity nanoscale biomaterials solid lipid nanoparticles thrombolytics |
| title | Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023) |
| title_full | Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023) |
| title_fullStr | Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023) |
| title_full_unstemmed | Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023) |
| title_short | Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023) |
| title_sort | targeting of nanoparticles towards blood brain barrier with a potential for the treatment of cerebrovascular disorders a systematic review 2017 2023 |
| topic | blood–brain barrier drug toxicity nanoscale biomaterials solid lipid nanoparticles thrombolytics |
| url | https://journals.lww.com/10.4103/JME.JME_155_23 |
| work_keys_str_mv | AT rajachakraverty targetingofnanoparticlestowardsbloodbrainbarrierwithapotentialforthetreatmentofcerebrovasculardisordersasystematicreview20172023 AT samarendranathsamui targetingofnanoparticlestowardsbloodbrainbarrierwithapotentialforthetreatmentofcerebrovasculardisordersasystematicreview20172023 AT tatinidebnath targetingofnanoparticlestowardsbloodbrainbarrierwithapotentialforthetreatmentofcerebrovasculardisordersasystematicreview20172023 |